The Gamaleya Center submitted documents to the Ministry of Health for the registration of an mRNA cancer vaccine.

The Gamaleya Center submitted documents to the Ministry of Health for the registration of an mRNA cancer vaccine.

      23 September 2025, 14:14

      Society

      The Gamaleya National Research Center for Epidemiology and Microbiology, the Herzen Moscow Oncology Institute, and the Blokhin National Research Center for Oncology have started clinical trials of a personalized mRNA cancer vaccine. In the first phase, two groups of 15 people each are taking part; they will receive the first doses of the drug within the next month and a half.

      Gamaleya Center director Alexander Gintsburg noted that registering the vaccine will take time, but the developers are confident of success. The drug is created individually for each patient based on the genetic data of samples from their tumors. The synthesis of sequences for the mRNA carriers is currently being completed, and after receiving permission from the Ministry of Health it is planned to produce 15–20 doses of the vaccine per patient.

      The first participants in the experiment are patients with melanoma. Head of the Federal Medical-Biological Agency Veronika Skvortsova reported positive results: the vaccine reduces tumor sizes and slows their growth. Next year it is planned to recruit another 15 patients to continue the trials.

      If the trials confirm its effectiveness, the mRNA vaccine will be provided to patients free of charge.

      NIA "Nizhny Novgorod" has a Telegram channel. Subscribe to stay informed of major events, exclusive materials, and timely information.

      Copyright © 1999–2025 NIA "Nizhny Novgorod". When reprinting, a hyperlink to NIA "Nizhny Novgorod" is required. This resource may contain 18+ materials.

Другие Новости Нижнего (Н-Н-152)

The Gamaleya Center submitted documents to the Ministry of Health for the registration of an mRNA cancer vaccine.